$GOVX News

GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift

GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers

GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event

Why Is GOVX Stock Falling Today?

GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)

How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms

GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms; Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses

Why Is GeoVax Labs Stock Falling Tuesday?

GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats

GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules

GeoVax Is The Holder Of Patent 11,701,418 Titled "Replication-deficient Modified Vaccinia Ankara (MVA) Expressing Ebola Virus Glycoprotein And Matrix Protein"

All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy

GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans

Geovax Labs Q1 EPS $(2.62) Beats $(4.42) Estimate

GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors